Since the last situational assessment shared with the EMA and European Commission on 6 November 2020, EFPIA/Vaccines Europe have regularly monitored the supply situation among their members. EFPIA and Vaccines Europe members do not report any current shortages of medicines across the European Union.

While they currently have no shortages to report, our member companies pointed out the following risks of shortages:

- For Valium (diazepam), as a result of an increase of demand following stockouts of other suppliers. The company is exploring options to increase supply and cover the demand.
- For Depo-Provera Vials, due to the prioritization of Covid Vaccine production, one manufacturer site will momentarily cease production as of 01-Feb-2021. The impact is a projected shortage of 1ml and 3ml & 3.3ml vials presentations, spread across all regions. The Depo-Provera syringe presentations are not impacted by this event. Notification to affected EU Member States is on-going (the product is nationally registered).

Without facing shortages for the time being, companies also reported the following challenges:

- Increase of demand on some products,
- Transportation capacity remains limited, with the Global air cargo capacity down by 18% and a shortage of sea freight equipment limiting global sea freight capacity,
- There are supply tensions on the provision of raw materials of biological products, since these raw materials are also used in vaccines production.